PCRX STOCKHOLDERS: Contact Robbins LLP for Information About the Pacira BioSciences, Inc. Class Action Before the Expiration of the Lead Plaintiff Deadline
February 27, 2025 17:19 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Pacira BioSciences, Inc. (PCRX) Failed to Disclose its Lack of Patent Protection for Exparel
TMDX Shareholders with Large Losses Should Contact Robbins LLP for Information About the Securities Class Action Against TransMedics Group, Inc.
February 25, 2025 17:50 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that TransMedics Group, Inc. (TMDX) Misled Investors Regarding its Coercive and Unsafe Business Practices
NTLA Investors are Suing Intellia Therapeutics, Inc.; Contact Robbins LLP for More Information
February 20, 2025 17:39 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Intellia Therapeutics, Inc. (NTLA) Misled Investors Regarding the Viability of its Drug Candidate
ICLR Investors are Suing ICON PLC; Contact Robbins LLP for More Information
February 20, 2025 17:28 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that ICON PLC (ICLR) Misled Investors Regarding Demand
BIOA STOCK NEWS: Robbins LLP Reminds BioAge Labs, Inc. Investors of the Pending Lead Plaintiff Deadline – March 10, 2025
February 18, 2025 21:17 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that BioAge Labs, Inc. (BIOA) Misled Investors Regarding its Lead Drug Candidate in Connection with its IPO
TransMedics Group, Inc. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against TMDX
February 18, 2025 21:10 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that TransMedics Group, Inc. (TMDX) Misled Investors Regarding its Coercive and Unsafe Business Practices
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK
February 18, 2025 20:09 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Merck & Co., Inc. (MRK) Misled Investors Regarding the Projected Revenue Outlook and Growth of Gardasil
NVO STOCK NEWS: NVO Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Novo Nordisk A/S
February 14, 2025 17:51 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity
EPIX STOCK NEWS: EPIX Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Essa Pharma Inc.
February 14, 2025 17:33 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that ESSA Pharma Inc. (EPIX) Misled Investors Regarding the Efficacy of its Drug Candidate Masofaniten
ModivCare, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the MODV Class Action Lawsuit
February 11, 2025 19:18 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that ModivCare, Inc. (MODV) Misled Investors Regarding its Business Prospects